$3.5M Grant to Test Continuous Glucose Monitoring for Type 2 Diabetes
The National Institutes of Health (NIH) announced on Sept. 1 that it was granting $3.5 million to Dan Cox, PhD, for a long-term study testing the use of continuous glucose monitoring in people with type 2 diabetes. Unlike a blood glucose meter that only measures blood sugar at a single point in time, a continuous glucose monitor, or CGM, is a device that provides a 24-hour record of blood sugar levels.
The grant was awarded based on the pilot trial that Dr. Cox and Mark Cucuzella, MD, conducted in 2022, on 17 adults with type 2 diabetes who used CGMs to guide their eating choices. After three months, nearly 70% of the participants achieved diabetes remission, meaning their HbA1c dropped below 6.5% without the use of medication.
Dr. Cox explained that teaching people how food intake, beverage consumption, and exercise affect their blood sugar encourages them to make healthy choices that can improve and in many cases reverse their diabetes. He calls his approach “Glucose Every Day Matters,” or GEM.
In the upcoming randomized controlled trial, 200 people recently diagnosed with type 2 diabetes will be followed for five years to see whether GEM improves their blood sugar control and decreases their need for diabetes medication.
Dr. Cox is a great example of his own approach, having maintained a HbA1c of less than 6% – down from 10.3% when first diagnosed with type 2 diabetes – for more than 13 years without taking any medication.
|